ESMO WCGIC 2023 | Biomarker-driven approaches for anal cancer

Sheela Rao, MBBS, FRCP, MD (Res), Royal Marsden Hospital, London, UK, discusses the future of studies surrounding anal cancer. As anal cancer is a rare cancer, limited translational study has been conducted. As there are many patients now with tissue, blood and circulating tumor HPV DNA, it is possible to delve into the biology of these cancers in local regional and advanced settings. This will hopefully allow for more biomarker-driven targeted approaches in the future. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.